Healthcare Services

Global CC Chemokine Receptor Type 5 Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The CC Chemokine Receptor Type 5 Market By 2030 Starting From Its 2026 Size?

The market size for cc chemokine receptor type 5 has shown considerable growth in recent years. This market is projected to expand from $1.54 billion in 2025 to reach $1.7 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.1%. Factors contributing to this historical growth include the discovery of ccr5 role in hiv infection, the early development of ccr5 inhibitors, the expansion of immunology research programs, clinical trials in inflammatory diseases, and the growth of targeted receptor therapies.

The cc chemokine receptor type 5 market is projected to experience substantial expansion in the coming years, anticipated to reach $2.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This growth throughout the forecast period can be attributed to several factors, including the broadening scope of personalized immunotherapies, advancements in HIV treatment innovation, the expansion of oncology drug development pipelines, increased investment in immune modulation research, and progress in targeted receptor drug design. Prominent trends observed over the forecast duration encompass the escalating development of CCR5 antagonist therapies, a heightened focus on HIV and immunology research, the widening application of CCR5 in oncology, the increasing embrace of targeted immune modulation strategies, and a stronger emphasis on precision drug development.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18290&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The CC Chemokine Receptor Type 5 Market?

The CC chemokine receptor type 5 market is projected to expand due to the rising occurrence of chronic diseases. These are defined as enduring medical conditions, including ailments like heart disease, diabetes, and arthritis, which develop gradually and typically necessitate continuous care. The increase in chronic disease prevalence is attributed to an aging global demographic and a rise in lifestyle-related risk factors such as unhealthy eating habits, lack of exercise, and excessive weight. In chronic conditions like human immunodeficiency virus (HIV), CC Chemokine Receptor Type 5 (CCR5) holds significant importance because it serves as a co-receptor, enabling the virus to penetrate and infect immune cells, thereby contributing significantly to disease progression. For example, data from April 2025, provided by the Centers for Disease Control and Prevention (CDC), a federal agency based in the U.S., indicated that about 194 million U.S. adults, representing 76.4%, reported having at least one chronic condition in 2023. This condition affected 59.5% of young adults, 78.4% of midlife adults, and 93.0% of older adults. Consequently, the increasing occurrence of chronic diseases is fueling the expansion of the CC chemokine receptor type 5 market.

Which Segment Categories Define The CC Chemokine Receptor Type 5 Market?

The cc chemokine receptor type 5 market covered in this report is segmented –

1) By Type: BMS-813160, AG-1105, DS-001, Other Types

2) By Distribution Channel: Hospitals, Clinics

3) By Application: Infectious Disease, Immunology, Oncology, Other Applications

4) By End User: Research Institutes, Pharmaceutical Companies, Healthcare Facilities

Subsegments:

1) By BMS-813160: CCR5 Antagonist For HIV Treatment, CCR5 Antagonist For Inflammatory Diseases

2) By AG-1105: CCR5 Antagonist For Autoimmune Disorders, CCR5 Antagonist For Cancer Therapy

3) By DS-001: CCR5 Inhibitor For Cancer Treatment, DS-001 For Inflammatory Disease Management

4) By Other Types: Novel CCR5 Antagonists, Dual-Target CCR5 Antagonists

What Key Trends Are Influencing The Development Of The CC Chemokine Receptor Type 5 Market?

Leading firms within the CC chemokine receptor type 5 market are concentrating on creating novel medications, specifically CCR5 antagonists, to achieve a competitive edge. A CC chemokine receptor type 5 (CCR5) antagonist functions by obstructing the CC chemokine receptor type 5 (CCR5) receptor found on immune cells, which in turn stops specific pathogens, including HIV, from attaching to and entering these cells, consequently hindering infection and regulating immune responses. An example is from February 2024, when CytoDyn Inc., an American biotechnology enterprise, disclosed that the U.S. Food and Drug Administration (FDA) removed the clinical hold previously placed on leronlimab. This authorization allows the company to move forward with its intended HIV clinical trial, aiming to examine leronlimab’s influence on chronic inflammation. Leronlimab, identified as a CCR5 antagonist and also known as PRO 140, demonstrates potential for diverse therapeutic uses because of its capacity to address numerous health conditions, with ongoing investigations for indications such as HIV and cancer.

Who Are The Top Companies Competing In The CC Chemokine Receptor Type 5 Market?

Major companies operating in the cc chemokine receptor type 5 market are Cytodyn Inc., Gilead Sciences Inc., ViiV Healthcare Limited, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, AbbVie Inc., AstraZeneca plc, Novartis AG, Sanofi SA, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Avexa Limited, Incyte Corporation, Humanigen Inc., Biogen Inc.

Read the full cc chemokine receptor type 5 market report here:

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Which Regions Are Projected To Dominate The CC Chemokine Receptor Type 5 Market In The Coming Years?

North America was the largest region in the CC chemokine receptor type 5 market in 2025. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored CC Chemokine Receptor Type 5 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18290&type=smp

Browse Through More Reports Similar to the Global CC Chemokine Receptor Type 5 Market 2026, By The Business Research Company

Cbd Nutraceuticals Global Market Report

https://www.thebusinessresearchcompany.com/report/cbd-nutraceuticals-global-market-report

Recreational Cannabis Global Market Report

https://www.thebusinessresearchcompany.com/report/recreational-cannabis-global-market-report

Cannabis Extract Global Market Report

https://www.thebusinessresearchcompany.com/report/cannabis-extract-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795